{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-135935","form_type":"8-K","ticker":"NUVB","cik":"0001811063","company_name":"Nuvation Bio Inc.","filed_at":"2023-05-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.751678+00:00","generated_at":"2026-06-15T22:47:47.750796+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Nuvation Bio Q1 2023 net loss $21.7M; cash $646.6M; DDC IND on track for year-end","bullets":["Net loss of $21.7M ($0.10 per share) vs $21.3M ($0.10) in Q1 2022.","Cash, cash equivalents and marketable securities of $646.6M as of March 31, 2023.","R&D expenses decreased to $18.8M from $20.7M, primarily due to headcount reduction and NUV-422 program termination.","Phase 1b combo study of NUV-868 with olaparib/enzalutamide and Phase 1 monotherapy study both enrolling.","IND submission for first Drug-Drug Conjugate candidate expected by year-end 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-135935","json":"https://secwatch.observer/filing/0001193125-23-135935.json","markdown":"https://secwatch.observer/filing/0001193125-23-135935.md","text":"https://secwatch.observer/filing/0001193125-23-135935.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1811063/000119312523135935/0001193125-23-135935-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1811063/000119312523135935/d301084d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T22:47:47.750796+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"551a59fbf1ced9fef59bcd86588709e0e3388769","claim":"Nuvation Bio Inc. reported the first quarter ended March 31, 2023 results: net income $21.7 million, EPS $(0.10) per share.","evidence_excerpt":"For the three months ended March 31, 2023, Nuvation Bio reported a net loss of $21.7 million, or $(0.10) per share.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1811063/000119312523135935/0001193125-23-135935-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2023"},{"label":"Net income","value":"$21.7 million"},{"label":"EPS","value":"$(0.10) per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}